Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Keryx Biopharmaceuticals Inc

+ Add to Watchlist

KYX:GR

9.675 EUR 0.355 3.81%

As of 13:55:39 ET on 05/29/2015.

Snapshot for Keryx Biopharmaceuticals Inc (KYX)

Open: 9.347 Day's Range: 9.123 - 9.675 Volume: 0
Previous Close: 9.320 52wk Range: 7.891 - 14.135 1-Yr Rtn: +1.96%

Stock Chart for KYX

No chart data available.
  • KYX:GR 9.188
  • 1D
  • 1M
  • 1Y
9.320
Interactive KYX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KYX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.9310
Est. PEG Ratio -
Market Cap (M EUR) 1,002.29
Shares Outstanding (M) 103.60
30 Day Average Volume 277
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KYX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for KYX

Keryx Biopharmaceuticals, Inc. is focused on developing and commercializing pharmaceuticals for the treatment of renal disease. The Company's product candidate completed Phase 3 testing, pursuant to an SPA agreement with the FDA, for hyperphosphatemia in ESRD patients. The product candidate is also in Phase 2 for non-dialysis dependent CKD patients with iron-deficiency anemia.

Gregory P Madison "Greg"President/COOJames F OlivieroCFO/Treasurer/Secretary
John F NeylanChief Medical OfficerBrian R AdamsVP/General Counsel
More Company Profile & Key Executives for KYX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil